TEM acquires Ambry Genetics, expanding its testing portfolio and redefining precision medicine. CHICAGO, November 25, 2024--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption ...

Acquisition Multiples: 1.9 times current revenue and roughly 15 times EBITDA. Tempus AI Inc (NASDAQ:TEM) reported a 33% revenue growth, reaching $180.9 million for Q3 2024. The company's data and ...